TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07288138: A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed M

Sponsor: Eccogene · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 160 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,263,800

Rescue Site Savings

+$1,499,400

Unlock Full NCT07288138 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07288138 Rescue Dossier →